Knowable Magazine reports that studying dogs' cancers offers insights into human cancer, due to similar pathways and faster ...

Researchers sought to determine whether subcutaneous isatuximab would be effective for patients with newly diagnosed MM who are ineligible for transplantation.

Cancer survival has doubled in the past half a century, but around 167,000 people still die of the disease in the UK every ...

According to Research by SNS Insider, U.S. Multiple Myeloma Market is projected to reach USD 13.91 Billion by 2032, as novel drug classes, immunotherapies, and diagnostic advances reshape treatment ...

Genmab's (GMAB) stock gains as its lymphoma drug epcoritamab developed with AbbVie (ABBV) succeeds in a Phase 3 lymphoma ...

An expert discusses the growing importance of real-world evidence in informing payer decisions and value-based care strategies for bispecific therapies in relapsed/refractory multiple myeloma (R/R MM) ...

Emma Charles shares her vision for healthcare, how AI is reshaping pharma and why access to innovation must be faster and ...

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting ...

PET/CT is a critical tool for MM staging, treatment response monitoring, and the detection of extramedullary disease (EMD), the authors explained. PET/CT has also been found to be a valuable ...

Pfizer Q2 2025 earnings show 10% revenue growth, raised EPS guidance, strong R&D, and operational execution. Explore growth drivers and policy risks.

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

Collaboration Revenue. Collaboration revenue was $7.6 million for the three months ended June 30, 2025, compared to $6.9 million for the three months ended June 30, 2024. The increase was driven by ...